Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren syndrome

Documenti analoghi

• Neovascularization is prominent in the chronic inflammatory lesions of Sjögren's syndrome
  di: Sisto, Margherita, et al.
  Pubblicazione: (2014)
• Understanding the Complexity of Sjögren’s Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms
  di: Sisto, Margherita, et al.
  Pubblicazione: (2020)
• Downstream activation of NF‐κB in the EDA‐A1/EDAR signalling in Sjögren's syndrome and its regulation by the ubiquitin‐editing enzyme A20
  di: Sisto, M., et al.
  Pubblicazione: (2016)
• Mycobacterium avium subspecies paratuberculosis infection and autoimmune condition: investigation of family members
  di: Margherita Sisto, et al.
  Pubblicazione: (2009-12-01)
• Raf Kinase Inhibitor Protein Interacts with NF-κB-Inducing Kinase and TAK1 and Inhibits NF-κB Activation
  di: Yeung, Kam C., et al.
  Pubblicazione: (2001)